Paper Details

  1. Home
  2. Paper Details

Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.

Author: CarlssonR M, GotheforsL, GustafssonL, HallanderH O, LjungmanM, NetterlidE, NilssonL, OlinP

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Two randomized booster trials investigated the immunogenicity and reactogenicity of Tdap vaccines in children and adolescents. Tdap5 induced comparable anti-PT concentrations at ages 5 and 15 years, but antibody responses to other pertussis antigens were significantly higher in adolescents. The frequency of adverse events was low in both age groups.
Paper Details　
Original Abstract of the Article :
Prior study children from a DTaP efficacy trial were recruited at ages 5 and 15 years to randomized booster trials addressing immunogenicity and reactogenicity; 475 preschool children received mixed or separate injections of a reduced antigen vaccine (Tdap5, Sanofi Pasteur MSD) and an inactivated po...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2015.05.079

データ提供：米国国立医学図書館（NLM）

Boosting Immunity Against Pertussis: A Study on Tdap Vaccine Efficacy

Pertussis, also known as whooping cough, is a highly contagious respiratory illness that can be particularly dangerous for infants. This study, published in [journal name], focuses on the efficacy of pertussis booster vaccines in children who were initially vaccinated with an acellular vaccine in infancy.

The authors conducted two consecutive randomized controlled trials, one involving preschool children aged 5 years and the other involving adolescents aged 14-15 years. The goal of these trials was to assess the immunogenicity and reactogenicity of different pertussis booster vaccines.

The study found that both the five-component Tdap vaccine (Tdap5) and the monocomponent Tdap vaccine (Tdap1) induced adequate antibody responses against pertussis antigens in both preschool children and adolescents. The authors also observed a low frequency of adverse events, indicating a good safety profile for these vaccines.

Strengthening Immunity: A Vital Step for Public Health

The study's findings provide valuable information about the efficacy and safety of pertussis booster vaccines in children. These findings are crucial for public health efforts aimed at controlling pertussis outbreaks.

The Power of Vaccination: Protecting Communities

This research underscores the importance of vaccination in protecting individuals and communities from preventable diseases. It's a reminder that vaccination is a cornerstone of public health and a vital tool for ensuring the well-being of our children.

Dr. Camel's Conclusion

This study, like a caravan carrying the precious cargo of immunity, provides evidence for the effectiveness and safety of pertussis booster vaccines. The findings underscore the vital role of vaccination in protecting our children and communities from this dangerous disease.

Date :
  1. Date Completed 2016-03-24
  2. Date Revised 2015-07-04
Further Info :

Pubmed ID

26057135

DOI: Digital Object Identifier

10.1016/j.vaccine.2015.05.079

Related Literature

Article Analysis
・Side Effects of polio vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.